Paul Scherrer Institute, Villigen, Switzerland Report issue

Academic/Hospital Phase 1

Organization Overview

First Clinical Trial
2015
NCT02088645
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Alternative names

Center for Proton Therapy, Paul Scherrer Institute, Villigen,Switzerland | Paul Scherrer Institut, Center for Proton Therapy | Paul Scherrer Institut, Villigen, Switzerland

Active Ingredients

Drugs in Phase 1 Trials (2)

177lu-pp-f11n (2 trials)

sacubitril (Entresto) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Thyroid Diseases (Phase 1)

Thyroid Neoplasms (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 2
  • # of Trial APIs: 2